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Objective: The availability of weekly subcutaneous infusions of subcutaneous immunoglobulin 
(SCIg) provides an additional therapeutic option for patients with primary immunodeﬁ  ciency 
disease. With proper patient education, individuals can safely transition to SCIg therapy and 
experience minimal side effects.
Research design: Case reports.
Results: A plan for successful implementation of SCIg therapy is presented. Case reports 
illustrate the how to manage the transition from IVIg to home infusion of SCIg. In Case 1, 
despite training, home infusion was complicated by infusion-site reactions, the most com-
mon adverse event. Troubleshooting by the medical staff identiﬁ  ed improper administration 
of SCIg, a correctable cause of reactions. In Case 2, patient education enabled this woman to 
successfully transition to SCIg without adverse effects, and without the headache and fatigue 
she experienced with IVIg.
Conclusions: Home infusion of SCIg can be successfully implemented with careful planning, 
patient/caregiver education, support, and follow-up.
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Introduction
SCIg therapy in primary immunodeﬁ  ciencies
Replacement immunoglobulin therapy for primary immunodeﬁ  ciency in the United 
States has, until recently, been administered almost exclusively via intravenous infu-
sions every two to four weeks. The availability of weekly subcutaneous infusions has 
expanded therapeutic options for many patients, most notably those unable to tolerate 
intravenous gamma globulin (IVIg) infusions. Severe systemic reactions, which are a 
major problem for some IVIg patients, occur less frequently with subcutaneous immu-
noglobulin (SCIg) therapy (Chapel et al 2000). In addition, SCIg avoids the need for 
intravenous access which is a major problem and complication risk for some patients. 
IVIg infusion patients with difﬁ  cult veins often require multiple puncture to establish 
an IV. Often, these patients have an implanted venous access device placed. These 
devices increase the risk of infection and create a new risk of thrombosis. All of these 
problems are eliminated with the use of SCIg. The relative ease of self-administration 
is also a signiﬁ  cant advantage for many patients, by decreasing visits to hospitals or 
infusions centers, which may be distant from the patients’ home, as well as increasing 
independence and scheduling ﬂ  exibility for the patient.
The most commonly reported adverse event in trials of SCIg therapy has been 
infusion-site reactions. These involve local swelling or redness and are usually mild. Patient Preference and Adherence 2008:2 164
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Examples of mild and moderate injection site reactions are 
shown in Figure 1. Reactions usually resolve spontaneously 
within 24 hours (Ochs et al 2006). Clinical studies have 
typically found that about 80%–90% of treatment-naïve 
SCIg patients experience these reactions (Table 1), but 
they are most often mild and rarely lead to discontinuation 
of therapy (Gardulf et al 1991, 1995, 2006; Abrahamsen 
et al 1996; Chapel et al 2000; Ochs et al 2006; Fasth and 
Nystrom 2007). One report of perceptions of infusion-site 
reactions in 152 SCIg recipients found that most did not 
view reactions as troublesome (Gardulf et al 1995b). Two 
recent trials reported a steady decrease in the incidence of 
infusion-site reactions with repeated infusions in patients 
new to SCIg therapy (Figure 2) (Gardulf et al 2006; Ochs 
et al 2006). Another recent trial in pediatric patients con-
ﬁ  rmed a decrease in injection site reactions during the ﬁ  rst 2 
months of therapy (Fasth and Nystrom, 2007). Also shown 
in Figure 2 is the extremely low rate of reactions reported 
in patients who had been previously treated with SCIg for 
several months. The authors suggested that tissue respon-
siveness may decrease over time when infusion sites are 
not varied.
Managing patient expectations
Preparing patients by addressing their expectations of treat-
ment and reported adverse events such as infusion-site reac-
tions during training will improve their infusion experience 
and increase their acceptance of SCIg. We recommend the 
following steps to maximize patient understanding of SCIg 
therapy:
•  The initial infusion or infusions should be performed 
by experienced professional staff to demonstrate that 
the technique can work with few to no problems. This 
allows the patient to initially focus on what is happening 
during the infusion, rather than what they will have to 
do. Once they have a general concept of the experience, 
they will expect good experiences going forward, and 
they are ready to be taught technique.
•  When training infusion technique, the setup and prepara-
tion should be clearly separated from the actual initiation 
of the infusion so that the patient/parent can focus on each 
step in the process.
•  Patients should be evaluated for infusion-site reactions 
during training, as well as educated on what reactions they 
might expect once they go home. Explanations should 
include information on what they can do to both decrease 
the likelihood of infusion-site reactions and to minimize 
discomfort that may occur. These explanations are more 
effective when they are a part of a direct discussion with 
the patient, even if the patient is a child. The informa-
tion should be clear, age appropriate and may need to 
be repeated at each of the training sessions. Equipment 
alternatives that can inﬂ  uence infusion-site reactions, 
such as needle, pump, and rate of infusion, should be 
spelled out. Patients should be aware that adjustments 
to the infusion regimen may be necessary until optimal 
tolerability is achieved. Patients should also be instructed 
to anticipate potential problems during the infusion, 
such as pain, redness, or the needle coming out, and the 
appropriate action.
•  Once patients are sent home to self-administer their infu-
sions, it is essential to provide telephone support during 
the ﬁ  rst several infusions. Patients should be encouraged 
to perform the ﬁ  rst one or two home infusions during 
regular hours to facilitate telephone support.
Mild
Moderate
Figure 1 Injection-site reactions following SCIg therapy. Examples of injection-site 
reactions that were classiﬁ  ed as mild and moderate are shown.Patient Preference and Adherence 2008:2 165
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•  Obtaining feedback on the process and problems is an 
important part of supervising home SCIg infusions. After 
the ﬁ  rst one or two home infusions, a telephone follow-up 
should be conducted to evaluate the infusion experience. 
If a patient reports repeated problems, he or she should 
be recalled for retraining to verify proper infusion tech-
nique.
•  As with any self-administered therapy, it is crucial to 
maintain a system for follow-up for patients admin-
istering SCIg at home because patients may neglect 
their follow-up appointments when doing home care. 
Some practitioners closely regulate gamma globulin 
homecare prescriptions to ensure regular follow-up.
Case studies
Case #1
RPD is a seven-year-old boy with common variable immu-
nodeﬁ  ciency (CVID) who experienced severe migraine 
headache for several days after IVIg infusions despite 
pre- and post-infusion medications. The change to SCIg infu-
sions in the immunologist’s ofﬁ  ce eliminated the headaches. 
The patient tolerated the ﬁ  rst infusions without complaint. 
Table 1 Injection-site reactions
Author  Year  n  # infusions  Total % patients   % reporting   % infusions   Withdrawals
      reporting  at  least  moderate  reporting
Gardulf 1991  25  3232    20%   
Gardulf 1995  158  33,168    19%   
Abrahamsen 1996 8  1100  87%  2.1%    0
Chapel 2000  30  1222      8.2% 
Gardulf 2006  60  2297  78%    28%  1
Ochs 2006  65  3656 91%    49%  3
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Figure 2 Injection-site reactions over time. The occurrence of injection-site reactions (of any severity) decreases over repeated SCIg administrations in subjects from two 
clinical trials, in North America (NA) and Europe (EU) (Gardulf et al 2006; Ochs et al 2006). Since SCIg therapy is common in Sweden, the subjects in the EU trial were divided 
into two groups: those with and without previous exposure to SCIg. After approximately 40 infusions, less than half of subjects continued to report injection-site reactions. 
Patients with previous experience with SCIg therapy reported very few reactions.Patient Preference and Adherence 2008:2 166
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Several additional subcutaneous infusions were administered 
without difficulty. The patient’s mother became more 
involved in administering the SCIg during each infusion. 
After the mother had started three infusions on her own but 
under supervision, further infusions were administered at 
home. A day after the next infusion, the mother reported 
the development of painful, 5-mm blisters at several of the 
infusion sites. The infusion nurse reviewed subcutaneous 
infusion technique with the mother including needle posi-
tioning, site location, and infusion rate. The following week, 
during the next infusion, the mother called to report that her 
son experienced intense pain one hour after starting the sub-
cutaneous infusion. The infusion was discontinued and the 
patient was scheduled for an appointment the following day. 
On examination, each infusion site exhibited an erythematous 
area with a central blister. During a careful procedure review 
with the infusion nurse, we learned that the mother was not 
placing the catheters into the subcutaneous tissue but rather 
had administered the SCIg intracutaneously.
Case #2
Subcutaneous gamma globulin therapy was initiated in a 40-
year-old woman with CVID who had previously been treated 
with IVIg. Her physician began by discussing the problems 
with headache and fatigue that she had been experiencing 
following her intravenous gamma globulin infusions. He 
suggested that patients who had these common problems 
with IVIg had fewer problems with SCIg. He also noted that 
some patients experienced infusion-site reactions, but that in 
the studies of the commercially available SCIg, the frequency 
and severity of those reactions decreased signiﬁ  cantly after 
the ﬁ  rst infusion and that by the fourth infusion, most people 
had few to no problems with their subcutaneous treatments. 
Prior to the ﬁ  rst infusion, the patient met with the infusion 
nurse who reviewed the procedures for subcutaneous gamma 
globulin therapy and introduced her to another patient who 
was receiving subcutaneous gamma globulin. During the 
discussion, the infusion nurse explained that some swelling 
and induration or “thickening” at the infusion site should be 
expected. She also mentioned that some people experience 
pain at the infusion site during or for a short time after the 
treatment. They discussed infusion-site selection, infusion 
duration, and the likelihood that the global infusion experi-
ence would be improved. The patient returned the following 
week for her ﬁ  rst subcutaneous infusion prepared to assist 
in her own care by choosing the infusion sites and learning 
about the infusion process. Because she knew what to expect 
from subcutaneous infusion therapy, she was less anxious 
about the new approach. There were no surprises and the 
experience was, indeed, more satisfactory than her previous 
intravenous treatments because severe headache, myalgias, 
and malaise did not occur.
Conclusions
Subcutaneous immunoglobulin therapy is a useful option for 
many patients because of better tolerability and the freedom 
to choose when and where they receive their gamma globulin 
supplementation. Since injection-site reactions are initially 
very common with this therapy, and are likely to be worse 
with improper infusion technique, it is essential to prepare 
patients for these reactions during training. Monitoring during 
the ﬁ  rst several patient/parent-initiated infusions, telephone 
backup when home therapy is started and close followup are 
key elements in successful home SCIg therapy. Infusion-site 
reactions are minimized by proper technique and expert 
follow-up can identify and correct errors that contribute to 
reactions enhancing adherence to the home regimen.
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